This NAICS page summarizes federal procurement activity for Pharmaceutical Preparation Manufacturing over the last 10 years, with $130.96 billion obligated across 222,900 award actions. The Department of Veterans Affairs, McKesson Corporation, and recent annual totals account for much of the activity in this sector.
NAICS Industry
NAICS 325412 Federal Contract Obligations (Last 10 Years)
FPDS procurement data for NAICS 325412, Pharmaceutical Preparation Manufacturing, covering obligations, award counts, agencies, vendors, and annual trends over the last 10 years.
Totals reflect readable and exact obligated values from the provided analysis window, and annual, agency, and vendor figures are limited to the rows supplied.
NAICS Code
325412
Industry
PHARMACEUTICAL PREPARATION MANUFACTURING
Total Obligated
130.96 billion
130,960,258,690.00
Award Actions
222,900
Average Action Value
587,529.20
About NAICS 325412 federal contract activity
NAICS 325412, Pharmaceutical Preparation Manufacturing, accounts for 130.96 billion in obligated federal spending across 222,900 awards over the last 10 years, with an average award value of 587,529.2. The profile is highly concentrated in a small set of large pharmaceutical and distribution vendors, while award volume remains broad across many transactions.
Agency demand and leading federal buyers
The Department of Veterans Affairs is the largest buyer in this NAICS, with 79.50 billion obligated across 29,231 awards, followed by the Department of the Army at 37.23 billion and the Office of Assistant Secretary for Preparedness and Response at 5.48 billion. Defense Logistics Agency stands out for volume rather than value, recording 142,699 awards but only 2.57 billion obligated, indicating a high-frequency procurement pattern. The Centers for Disease Control and Prevention rounds out the top five with 2.07 billion.
Vendor concentration and leading contractors
McKesson Corporation is the dominant vendor with 80.49 billion obligated across 41,039 awards, far exceeding every other supplier in the category. Pfizer Inc. is second at 17.68 billion, followed by ModernaTx, Inc. at 8.20 billion and Eli Lilly and Company at 4.67 billion. GlaxoSmithKline LLC adds another 2.39 billion, reinforcing that spending is concentrated among major branded pharmaceutical manufacturers and large distribution intermediaries.
Annual contract trend over the analysis window
Annual obligations show elevated spending in 2021 and 2022, at 25.56 billion and 27.60 billion respectively, before declining to 10.65 billion in 2023 and 10.28 billion in 2024. Obligations increased again in 2025 to 14.61 billion, while award counts remained high throughout the period, ranging from 22,222 in 2021 to 30,184 in 2025. The pattern suggests sustained procurement activity with notable year-to-year volatility in dollar value.
How to interpret this page
This summary is based on FPDS obligations tied to NAICS 325412 over the last 10 years and reflects only the values provided in the source dataset. Rankings are determined by total obligated dollars, with award counts used to contextualize procurement concentration and transaction volume. No additional normalization, inflation adjustment, or external enrichment was applied.
Top Agencies
SELECT
agency_id,
agency_name,
total_obligated,
award_count,
formatReadableQuantity(total_obligated) AS total_obligated_readable
FROM
(
SELECT
content__award__purchaserInformation__contractingOfficeAgencyID AS agency_id,
anyHeavy(content__award__purchaserInformation__contractingOfficeAgencyID__name) AS agency_name,
sum(content__award__dollarValues__obligatedAmount) AS total_obligated,
count() AS award_count
FROM fpds.data
WHERE
contract_type = 1
AND content__award__productOrServiceInformation__principalNAICSCode = '325412'
AND content__award__purchaserInformation__contractingOfficeAgencyID IS NOT NULL
AND content__award__purchaserInformation__contractingOfficeAgencyID != ''
AND parseDateTimeBestEffortOrNull(content__award__relevantContractDates__signedDate) >= toStartOfYear(now()) - INTERVAL 10 YEAR
AND parseDateTimeBestEffortOrNull(content__award__relevantContractDates__signedDate) < toStartOfYear(now())
GROUP BY agency_id
)
ORDER BY total_obligated DESC
LIMIT 10| Agency ID | Agency Name | Total Obligated | Readable | Award Actions |
|---|---|---|---|---|
| 3600 | VETERANS AFFAIRS, DEPARTMENT OF | 79,496,219,989.05 | 79.50 billion | 29,231 |
| 2100 | DEPT OF THE ARMY | 37,234,422,114.22 | 37.23 billion | 2,046 |
| 7505 | OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE | 5,484,701,210.67 | 5.48 billion | 793 |
| 97AS | DEFENSE LOGISTICS AGENCY | 2,565,737,248.67 | 2.57 billion | 142,699 |
| 7523 | CENTERS FOR DISEASE CONTROL AND PREVENTION | 2,071,332,533.40 | 2.07 billion | 468 |
| 7527 | INDIAN HEALTH SERVICE | 1,724,158,345.99 | 1.72 billion | 1,797 |
| 1540 | FEDERAL PRISON SYSTEM / BUREAU OF PRISONS | 1,398,000,544.90 | 1.40 billion | 41,431 |
| 7529 | NATIONAL INSTITUTES OF HEALTH | 705,497,443.82 | 705.50 million | 1,427 |
| 5700 | DEPT OF THE AIR FORCE | 140,550,027.54 | 140.55 million | 114 |
| 97DH | DEFENSE HEALTH AGENCY (DHA) | 31,154,413.74 | 31.15 million | 488 |
Insight
Over the last 10 years, NAICS 325412 obligations totaled $130.96 billion across 222,900 awards, with spending highly concentrated in a few agencies. The Department of Veterans Affairs led by a wide margin with $79.50 billion, followed by the Department of the Army at $37.23 billion; together they accounted for most obligated dollars in this category. Award volume was more dispersed, driven notably by the Defense Logistics Agency with 142,699 awards despite only $2.57 billion obligated, while the Bureau of Prisons and Veterans Affairs also recorded large award counts.
Top Vendors
SELECT
vendor_name,
cage_code,
total_obligated,
award_count,
formatReadableQuantity(total_obligated) AS total_obligated_readable
FROM
(
SELECT
content__award__vendor__vendorHeader__vendorName AS vendor_name,
anyHeavy(content__award__vendor__vendorSiteDetails__entityIdentifiers__cageCode) AS cage_code,
sum(content__award__dollarValues__obligatedAmount) AS total_obligated,
count() AS award_count
FROM fpds.data
WHERE
contract_type = 1
AND content__award__productOrServiceInformation__principalNAICSCode = '325412'
AND content__award__vendor__vendorHeader__vendorName IS NOT NULL
AND content__award__vendor__vendorHeader__vendorName != ''
AND parseDateTimeBestEffortOrNull(content__award__relevantContractDates__signedDate) >= toStartOfYear(now()) - INTERVAL 10 YEAR
AND parseDateTimeBestEffortOrNull(content__award__relevantContractDates__signedDate) < toStartOfYear(now())
GROUP BY vendor_name
)
ORDER BY total_obligated DESC
LIMIT 10| Vendor | CAGE Code | Total Obligated | Readable | Award Actions |
|---|---|---|---|---|
| MCKESSON CORPORATION | 1MKG3 | 80,490,578,430.13 | 80.49 billion | 41,039 |
| PFIZER INC. | 86491 | 17,679,505,745.32 | 17.68 billion | 4,109 |
| MODERNATX, INC. | 6RP85 | 8,204,918,580.62 | 8.20 billion | 36 |
| ELI LILLY AND COMPANY | 75602 | 4,666,609,740.80 | 4.67 billion | 23 |
| GLAXOSMITHKLINE LLC | 667E9 | 2,392,109,126.71 | 2.39 billion | 1,152 |
| MERCK SHARP & DOHME CORP. | 6B2S4 | 2,209,550,547.33 | 2.21 billion | 174 |
| MODERNA US, INC. | 8PTM0 | 1,788,399,999.00 | 1.79 billion | 12 |
| ASTRAZENECA PHARMACEUTICALS LP | 36WK2 | 1,233,710,144.42 | 1.23 billion | 35 |
| BAVARIAN NORDIC A/S | R5853 | 1,167,279,477.00 | 1.17 billion | 21 |
| QUIDEL CORPORATION | 0TH42 | 682,965,184.50 | 682.97 million | 1,298 |
Insight
Over the last 10 years, NAICS 325412 obligations totaled $130.96 billion across 222,900 awards, indicating a highly concentrated vendor base. McKesson Corporation accounts for $80.49 billion, or about 61.5% of total obligated dollars, and Pfizer Inc. adds another $17.68 billion, bringing the top two vendors to roughly 75% of total obligations. The remaining top vendors are much smaller by obligated value, with several firms showing relatively few awards but high dollar totals, consistent with large, sporadic procurement activity.
Annual Trend
SELECT
year,
total_obligated,
award_count,
formatReadableQuantity(total_obligated) AS total_obligated_readable
FROM
(
SELECT
toYear(parseDateTimeBestEffortOrNull(content__award__relevantContractDates__signedDate)) AS year,
sum(content__award__dollarValues__obligatedAmount) AS total_obligated,
count() AS award_count
FROM fpds.data
WHERE
contract_type = 1
AND content__award__productOrServiceInformation__principalNAICSCode = '325412'
AND parseDateTimeBestEffortOrNull(content__award__relevantContractDates__signedDate) >= toStartOfYear(now()) - INTERVAL 10 YEAR
AND parseDateTimeBestEffortOrNull(content__award__relevantContractDates__signedDate) < toStartOfYear(now())
GROUP BY year
)
ORDER BY year DESC| Year | Total Obligated | Readable | Award Actions |
|---|---|---|---|
| 2025 | 14,614,912,143.60 | 14.61 billion | 30,184 |
| 2024 | 10,275,730,783.14 | 10.28 billion | 25,575 |
| 2023 | 10,653,562,406.33 | 10.65 billion | 24,144 |
| 2022 | 27,600,629,983.31 | 27.60 billion | 23,200 |
| 2021 | 25,560,611,597.63 | 25.56 billion | 22,222 |
| 2020 | 13,469,450,366.14 | 13.47 billion | 19,509 |
| 2019 | 6,604,828,858.75 | 6.60 billion | 17,163 |
| 2018 | 6,825,168,058.98 | 6.83 billion | 21,439 |
| 2017 | 8,473,230,660.70 | 8.47 billion | 17,553 |
| 2016 | 6,882,133,831.42 | 6.88 billion | 21,911 |
Insight
Over the last 10 years, NAICS 325412 obligated $130.96 billion across 222,900 awards, with an average award value of $587,529. Funding is concentrated in recent years, rising from a low of $6.60 billion in 2019 to a peak of $27.60 billion in 2022, before easing to $10.28 billion in 2024 and increasing to $14.61 billion in 2025. Award volume also accelerated over the period, reaching 30,184 awards in 2025 versus 17,163 in 2019, indicating higher transaction activity even as annual obligations remained uneven.
Use FPDS Query for deeper industry analysis
Explore federal procurement data with custom SQL, fast filtering, and deeper industry analysis across agencies, vendors, and annual trends.
Continue from this last 10 years view into full FPDS Query workflows with deeper filtering, custom SQL, saved queries, and broader market comparison.